Legend Biotech (LEGN) Financials: Revenue & Earnings
LEGN$22.34+0.78 +3.62%
$4.13B
Market Cap
-38.02
P/E
41.26
Forward P/E
62
Score
Legend Biotech (LEGN) Financials: Revenue & Earnings
LEGN price $22.34 +0.78 +3.62%
- Ticker
- LEGN
- Price
- $22.34
- Change
- +0.78 +3.62%
- Market cap ?
- $4.13B
- P/E ?
- -38.02
- Forward P/E ?
- 41.26
- Dividend yield ?
- 0.00%
- Beta ?
- 0.40
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 62
- Value
- 39
- Quality
- 48
- Growth
- 100
Stocklytics score rationale: value 39, quality 48, growth 100.
Financials
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 23594000 | 49133000 | 61800000 | 75000000 | 68826000 | 117005000 | 285143000 | 627241000 | 1028900000 |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM)…
Fair value
LEGN fair value $25.51. Price $22.34. Price is 12% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 100.83M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 184.94M. Net debt -488.20M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-11 | — | 0.01 | — | 361.46M |
| 2026-08-11 | 0.09 | 0.12 | 387.50M | 355.96M |
| 2026-05-12 | -0.15 | -0.02 | 305.10M | 306.51M |
| 2026-03-10 | -0.08 | -0.17 | 306.30M | 307.76M |
| 2025-11-12 | -0.11 | -0.13 | 272.33M | 274.42M |
| 2025-08-11 | -0.34 | -0.11 | 255.06M | 228.96M |
| 2025-05-13 | -0.07 | -0.23 | 195.05M | 193.65M |
| 2025-03-11 | -0.15 | -0.25 | 186.52M | 178.88M |
| 2024-11-12 | -0.34 | -0.35 | 160.21M | 143.91M |
| 2024-08-09 | -0.05 | -0.54 | 186.52M | 125.25M |
| 2024-05-13 | -0.16 | -0.29 | 93.99M | 143.24M |
| 2024-03-11 | -0.40 | -0.70 | 79.46M | 94.08M |
| 2023-11-20 | -0.17 | -0.56 | 96.01M | 97.25M |
| 2023-08-15 | -1.14 | -0.69 | 73.33M | 56.64M |
| 2023-05-18 | -0.40 | -0.56 | 36.34M | 42.18M |
| 2023-02-17 | -0.41 | -0.44 | 27.52M | 36.06M |
| 2022-06-01 | -0.26 | -0.46 | 40.83M | 25.00M |
| 2022-03-18 | -0.30 | -0.35 | 38.99M | 14.27M |
| 2021-11-16 | -0.43 | -0.35 | 16.88M | 7.83M |
| 2021-08-23 | -0.32 | -0.31 | 20.83M | 7.83M |
| 2021-05-18 | -0.30 | -0.35 | 14.30M | 15.64M |
| 2021-03-18 | -0.22 | -0.28 | 41.20M | 13.00M |
| 2020-11-16 | -0.50 | -0.31 | 12.46M | 11.25M |
| 2020-08-28 | -1.26 | -0.26 | 11.60M | 29.71M |
| 2020-06-08 | -0.34 | — | 12.66M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-29 | Sanders Corazon (Corsee) D. | Sell | 27.37K | $9.46 | 258.92K |
| 2026-09-24 | Salovey Peter | Buy | 28.33K | — | — |
| 2026-09-24 | Heyman Tomas J. | Buy | 20.99K | — | — |
| 2026-09-24 | Mao Li | Buy | 20.99K | — | — |
| 2026-09-24 | Casey Patrick John | Buy | 20.99K | — | — |
| 2026-09-24 | Ji Darren Xiaohui | Buy | 28.33K | — | — |
| 2026-09-24 | Sanders Corazon (Corsee) D. | Buy | 20.99K | — | — |
| 2026-09-21 | Santos Carlos E | Buy | 19.68K | — | — |
| 2026-09-21 | Santos Carlos E | Sell | 5.43K | $9.14 | 49.63K |
| 2026-09-15 | Zhang Ingrid | Buy | 1.13M | — | — |
| 2026-09-15 | Zhang Ingrid | Other | 0 | — | — |
| 2026-08-14 | BASH ALAN | Buy | 4.91K | — | — |
| 2026-07-24 | BASH ALAN | Other | 0 | — | — |
| 2026-06-30 | Casey Patrick John | Sell | 6.00K | $14.80 | 88.80K |
| 2026-06-30 | Huang Ying | Sell | 3.38K | — | — |
| 2026-06-25 | Huang Ying | Sell | 5.57K | $14.78 | 82.27K |
| 2026-03-25 | Huang Ying | Sell | 9.94K | $8.77 | 87.14K |
| 2026-03-18 | Heyman Tomas J. | Other | 0 | — | — |
| 2026-03-18 | Heyman Tomas J. | Other | 30.00K | $23.27 | 698.10K |
| 2026-03-18 | Meng Robin | Other | 0 | — | — |
| 2026-03-18 | Salovey Peter | Other | 0 | — | — |
| 2026-03-18 | Casey Patrick John | Other | 0 | — | — |
| 2026-03-18 | Casey Patrick John | Other | 30.00K | $14.12 | 423.60K |
| 2026-03-18 | Kung Gareth | Other | 0 | — | — |
| 2026-03-18 | Mao Li | Other | 0 | — | — |
| 2026-03-18 | Mao Li | Other | 30.00K | $23.27 | 698.10K |
| 2026-03-18 | Ji Darren Xiaohui | Other | 0 | — | — |
| 2026-03-18 | Ji Darren Xiaohui | Other | 30.00K | $11.50 | 345.00K |
| 2026-03-18 | Zhang Fangliang | Other | 0 | — | — |
| 2026-03-18 | Santos Carlos E | Other | 0 | — | — |
| 2026-03-18 | Sanders Corazon (Corsee) D. | Other | 0 | — | — |
| 2026-03-18 | Sanders Corazon (Corsee) D. | Other | 12.00K | $11.50 | 138.00K |
| 2026-03-18 | Huang Ying | Other | 0 | — | — |
| 2026-03-18 | Huang Ying | Other | 121.75K | $1.50 | 182.62K |
| 2026-03-18 | Huang Ying | Other | 185.34K | $27.50 | 5.10M |
| 2026-03-18 | Huang Ying | Other | 55.75K | $23.53 | 1.31M |
| 2026-03-18 | Huang Ying | Other | 92.13K | $14.12 | 1.30M |
| 2026-03-18 | Wang Ye | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 230, holders +21 vs prior quarter. Ownership 55.11%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 29.09M | 3.40M | +13.22% | 840.23M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 8.14M | 450.00K | +5.85% | 235.01M |
| MONTANOVA CAPITAL, LLC | 7.07M | -511.03K | -6.74% | 204.18M |
| HHLR ADVISORS, LTD. | 5.98M | 0 | 0.00% | 172.83M |
| BLACKROCK, INC. | 4.73M | 41.99K | +0.90% | 136.50M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4.43M | -1.33M | -23.14% | 127.94M |
| GOLDMAN SACHS GROUP INC | 3.66M | 2.20M | +150.14% | 105.77M |
| POINT72 ASSET MANAGEMENT, L.P. | 3.08M | -809.89K | -20.84% | 88.84M |
| KYNAM CAPITAL MANAGEMENT, LP | 3.00M | 1.42M | +90.40% | 86.67M |
| ASSENAGON ASSET MANAGEMENT S.A. | 1.92M | 1.92M | New | 55.31M |
| ARTISAN PARTNERS LIMITED PARTNERSHIP | 1.56M | -695.05K | -30.83% | 45.04M |
| STATE STREET CORP | 1.50M | 332 | +0.02% | 43.29M |
| CAPITAL INTERNATIONAL INVESTORS | 1.42M | 772.80K | +119.29% | 41.03M |
| MORGAN STANLEY | 1.39M | 791.28K | +131.17% | 40.27M |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.21M | 1.21M | New | 34.80M |
| DAVERN CAPITAL PARTNERS, LP | 1.19M | -123.23K | -9.37% | 34.41M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.16M | 1.16M | New | 33.47M |
| RENAISSANCE TECHNOLOGIES LLC | 1.00M | 478.40K | +91.68% | 28.89M |
| GHISALLO CAPITAL MANAGEMENT LLC | 1.00M | 1.00M | New | 28.88M |
| MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 917.27K | -8.65K | -0.93% | 26.49M |
| JOHNSON & JOHNSON | 814.59K | 0 | 0.00% | 23.53M |
| IVYROCK ASSET MANAGEMENT (HK) LTD | 801.00K | -3.00K | -0.37% | 23.13M |
| ECOR1 CAPITAL, LLC | 800.00K | 800.00K | New | 23.10M |
| JPMORGAN CHASE & CO | 766.36K | 478.26K | +166.00% | 22.52M |
| SQUAREPOINT OPS LLC | 769.25K | 289.77K | +60.43% | 22.22M |
Earnings and financials
Legend Biotech Corporation (LEGN) trades at $22.34, with a market cap of $4.13B and a trailing P/E of -38.02. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 23594000 | 49133000 | 61800000 | 75000000 | 68826000 | 117005000 | 285143000 | 627241000 | 1028900000 |
Insights · Dividends · Forecast · Financials · Learn